UNSPSC 51171648: Bisoxatin acetate

This classification denotes an oxazine C24H19NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 79W5LFS83K, chemically known as 2h-1,4-benzoxazin-3(4h)-one, 2,2-bis(4-(acetyloxy)phenyl)-, but more generally known as bisoxatin acetate, which bears US NIH Compound Identifier 26391. European Medicines Agency schedules Bisoxatin acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00833MIG. Most nations, for tariff and trade purposes, schedule bisoxatin acetate under HS 29349990 and SITC 51579.

As of Q4 2014, BISOXATIN ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OC1CCC(CC1)C2(C(=O)NC3CCCCC3O2)C4CCC(CC4)OC(=O)C.

UNSPSC 51171648 Bisoxatin acetate is a Commodity code that nominally identifies a specific pharmaceutical active ingredient, though recent state and local solicitations tagged with this code show minimal direct relevance to bisoxatin acetate itself. Instead, the code appears in procurement activity spanning drug testing services, pharmaceutical supply contracts, and pharmacy benefit program initiatives across Texas and multistate cooperative purchasing vehicles. The actual buying under this code encompasses specimen collection and immunoassay drug screening (with LC/MS/MS or GC/MS confirmation), generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers, and exploratory procurement for direct-to-manufacturer prescription programs. Issuing bodies include county corrections and community supervision departments (Collin County), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon).

Geographic activity centers on Texas and the Upper Midwest multistate cooperative region. Recent opportunities include Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 and a term of two years commencing September 1, 2026 with three optional one-year renewals; the Texas Health and Human Services Commission's RFI HHS0017013 for therapeutic pharmacy initiative direct-to-manufacturer prescription capabilities, posted April 3, 2026 as a preliminary market intelligence tool with no award value specified; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, serving participating state and local government facilities with a two-year initial term and optional extensions through June 30, 2028. The mismatch between the code's nominal pharmaceutical ingredient scope and the testing-services and supply-chain activity actually being solicited suggests either tagging imprecision or that bisoxatin acetate is a minor input in broader pharmaceutical procurement workflows.